Physician profile
Keith Zaitoun
NPI 1679567820
$1,606.59
in general payments reported to CMS, 2019-2025
22 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.69 · 2021: $293 · 2022: $229 · 2023: $252 · 2024: $430 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.13 |
| Education | $110.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $183.30 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $179.41 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $177.93 | 2019-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $141.36 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $99.02 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $98.62 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $88.10 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $87.74 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $78.52 | 2021-2024 | Jynarque |
| Akebia Therapeutics INC | $69.26 | 2023-2024 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $61.96 | 2021-2024 | Rayaldee |
| Novo Nordisk INC | $59.27 | 2023-2024 | Ozempic, Rybelsus |
| Ardelyx, INC. | $39.11 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $35.54 | 2023 | Krystexxa |
| Vantive US Healthcare LLC | $30.79 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.07 | 2025 | Gazyva |
| Novartis Pharmaceuticals Corporation | $29.47 | 2024 | |
| Mallinckrodt Hospital Products INC. | $26.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.65 | 2025 | Jardiance |
| Baxter Healthcare | $24.99 | 2022 | |
| Lilly USA, LLC | $20.21 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $20.07 | 2024 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Zaitoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.